Peer-influenced content. Sources you trust. No registration required. This is HCN.

MDLinxCan This Supplement Stave Off Dementia?

Unraveling the Potential of Nicotinamide in Mitigating Cognitive Decline: Insights and Cautions for Physicians

In the quest to address the complexities of cognitive decline, recent studies have spotlighted nicotinamide, a form of vitamin B3, for its potential in ameliorating conditions like Alzheimer’s disease (AD). Through various mechanisms such as tackling amyloid-beta and tau pathologies, reducing neuroinflammation, and supporting mitochondrial function, nicotinamide shows promise in improving brain health. However, caution is warranted due to concerns regarding excessive intake and associated risks, emphasizing the need for medical supervision in its use.

Key Points:

  • Nicotinamide, a derivative of vitamin B3, exhibits potential in mitigating cognitive decline associated with conditions like Alzheimer’s disease (AD) by addressing various pathological mechanisms such as amyloid-beta and tau pathologies, neuroinflammation, and mitochondrial dysfunction.
  • Research suggests that nicotinamide supplementation can improve symptoms of neurodegenerative diseases and promote myelin regeneration, offering hope for therapeutic interventions.
  • However, caution is advised regarding unsupervised consumption of nicotinamide supplements due to risks of toxicity, including liver damage and gastrointestinal symptoms.
  • Although studies show promising results, the long-term effects of nicotinamide supplementation remain unclear, warranting further research to fully understand its implications for cognitive health.
  • Physicians are encouraged to educate patients on obtaining vitamin B3 from dietary sources like poultry, beef, fish, nuts, legumes, and grains, and to discourage unsupervised use of nicotinamide supplements.
  • The FDA has prohibited the marketing and sale of nicotinamide mononucleotide (NMN) as a dietary supplement due to its classification as a potential new drug, highlighting the need for rigorous evaluation of nicotinamide derivatives as therapeutic agents.

Alzheimer’s disease (AD) is the most common neurodegenerative condition, expected to affect approximately 13.8 million people in the US by 2060.

More on Vitamins/Supplements

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form